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Abstract
Background: Understanding the population genetics of pneumococci will allow detection of changes in the prevalence
of circulating genotypes and evidence for capsular switching. We aimed to analyze the genetic structure of invasive
pneumococcal isolates obtained from children before and after the use of pneumococcal conjugate vaccines (PCVs)
in Korea.
Methods: A total of 285 invasive pneumococcal isolates were analyzed using serotyping, multilocus sequence typing,
and antimicrobial susceptibility testing. We classified the isolation year to pre-PCV7 (1995–2003; n = 70), post-PCV7
(2004–2010; n = 142), and post-PCV13 (2011–2013; n = 73) periods.
Results: Of the 10 clonal complexes (CCs), antibiotic-resistant international clones, CC320 (31.6%), CC81 (14.7%), and
CC166 (6.7%) were the main complexes. Serotype 19A was the main serotype of CC320 throughout the periods.
Serotypes of CC81 mainly comprised of 23F (53.3%) in pre-PCV7 period and replaced by non-vaccine types (NVTs;
6C [10%], 13 [30%], 15A [40%], and 15B/C [20%]) in post-PCV13 period. The main serotype responsible for CC166 also
changed from 9 V (80%) in pre-PCV7 to NVT 11A (50%) in post-PCV13 periods. Non-susceptibility to penicillin (42.3%)
was the highest in CC320, increasing from 0 to 76%.
Conclusion: The genetic structures of invasive pneumococcal isolates in Korean children have changed concomitantly
with serotype after the implementation of PCVs.
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Background
Pneumococcal conjugate vaccines (PCVs) targeting
previously predominant invasive serotypes has been
highly successful in decreasing the incidence of invasive
pneumococcal disease (IPD) and pneumococcal anti-
microbial resistance [1, 2]. However, individual variants
that originated through serotype switching have substan-
tially contributed to the disease burden in the
post-7-valent PCV (PCV7) era [3]. Additionally, clonal
expansion is considered to be a main mechanism for
ongoing antibiotic resistance [4]. Since serotype and
genotype are closely associated, changes in the circulat-
ing serotype have also resulted in a concomitant change
in the circulating genotype [5, 6]. Therefore, information
on both the genetic background and the capsular
serotype allowed us to analyze the responses to vaccine
implementation [7, 8].
PCV7 was introduced in Korea in November 2003 for
optional use. In June 2010, 10- and 13-valent PCVs
(PCV10 and PCV13) were introduced to replace PCV7.
In May 2014, both PCV10 and PCV13 were included in
the national immunization program (NIP) for children
under 60 months of age. Korea is one of a few countries
where both PCV10 and PCV13 are included in NIP.
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Studies on serotype changes in IPD after each PCV7 and
PCV10/13 implementation have been conducted [9, 10],
but the genetic backgrounds of IPD isolates have been
investigated only in the pre-PCV7 era thus far [11].
Therefore, we aimed to characterize the changes in gen-
etic structures of invasive pneumococcal isolates ob-
tained from children before and after the optional use of
PCV7 and PCV10/13 in Korea.
Methods
Subjects
Hospital-based surveillance to monitor pneumococcal
diseases as part of routine clinical care at Seoul National
University Children’s Hospital (SNUCH) has been
employed since 1991. In 2006, a nation-wide surveillance
system to monitor IPD began with 8 teaching hospitals,
including SNUCH. In 2011, the surveillance system was
expanded to include 25 hospitals throughout Korea. In
this study, IPD cases and corresponding pneumococcal
isolates obtained from children aged < 18 years were in-
cluded. This study was approved by the Institutional
Review Board of Seoul National University Hospital (IRB
registration number 1106–015-364) and each participat-
ing institute. Informed consent was waived, because the
study was retrospective and the pneumococcal isolates
were obtained as a standard part of routine patient care.
To explore the changes in genetic background following
the implementation of PCV7 and PCV10/13, we
grouped the isolation years to pre-PCV7 (1995–2003),
post-PCV7 (2004–2010), and post-PCV13 (2011–2013)
periods.
Isolates and serotyping
All pneumococcal isolates obtained from IPD cases were
sent to SNUCH, and serotype determination was
performed using the Quellung reaction with antisera
(Statens Serum Institut, Copenhagen, Denmark) and
polymerase chain reaction (PCR) [12]. A case of IPD
was defined as an infection confirmed by the isolation of
pneumococci from a normally sterile site, such as the
blood, cerebrospinal fluid, pleural fluid, ascites, or joint
fluid. For multiple isolates collected from a single epi-
sode of infection, only the initial isolate was included.
Serotypes 4, 6B, 9 V, 14, 18C, 19F, and 23F were classi-
fied as PCV7 types. The PCV13 types included six
PCV13-additional (aPCV13) serotypes: 1, 3, 5, 6A, 7F,
and 19A. The non-PCV types (NVTs) included all other
serotypes. All serotype data on study isolates were ex-
tracted from previous studies [9–11].
Multilocus sequence typing
Genomic DNA templates were prepared from pure
Streptococcus pneumoniae cultures according to the
manufacturer’s instructions (Qiagen, Manchester, UK).
The sequences of 7 housekeeping genes (aroe, gdh, gki,
recP, spi, xpt, and ddl) were used in the pneumococcal
multilocus sequence typing (MLST) scheme as previ-
ously described [13]. New alleles and sequence types
(STs) were submitted to the MLST web database
(https://pubmlst.org) for assignment. eBURST v3 soft-
ware, which is available on the MLST website, was used
to estimate the relationships among the isolates and to
assign the strains to a clonal complex (CC) [14]. Single-
and double-locus variants (SLVs and DLVs, respectively)
were defined as STs differing from the confounding ST
at one and two loci, respectively. MLST data on 77
pneumococci isolated from 1995 to 2005 were obtained
from a previous IPD study [11]. Data on all serogroup 6
(n = 35) were also a part of a previous publication [15].
Antimicrobial susceptibility testing
A total of 236 pneumococcal isolates were tested to de-
termine the minimal inhibitory concentrations (MICs) of
8 antimicrobial drugs (penicillin, cefotaxime, chloram-
phenicol, tetracycline, clindamycin, erythromycin,
trimethoprim-sulfamethoxazole, and levofloxacin) using
the E-test (bioMérieux, Marcy l’Etoile, France). Only
MIC data on all isolates (n = 73) from 2011 to 2013 were
produced in this study, whereas those of isolates from
1995 to 2010 were extracted from previous studies. Forty
randomly selected isolates among the 77 invasive
pneumococci from 1995 to 2005 [11] and most isolates
(n = 123) - with the exception of 12 strains that failed to
regrow - from 2006 to 2010 [9] were included in the
analysis. The breakpoints described in the 2014 Clinical
and Laboratory Standards Institute (CLSI) guideline
were used [16]. Non-meningitis criteria of parenteral
drugs were used for penicillin (2.0 μg/mL) and cefotax-
ime (1.0 μg/mL).
Statistical analysis
Statistical analysis was performed using SPSS Statistics,
version 23.0 (IBM Corp., Armonk, NY). Rates and
proportions were compared using the chi-square test or
Fisher’s exact test, where appropriate. A P value < 0.05
was considered statistically significant.
Results
Isolate and serotype distributions in pre- and post-PCV
periods
A total of 285 invasive pneumococcal isolates were in-
cluded in the analysis: 77 (27.0%) isolates at SNUCH
from 1995 to 2005 and 208 (73.0%) isolates at 8 centers
from 2006 to 2010 (n = 135) and 25 centers from 2011
to 2013 (n = 73). Pre-PCV7, post-PCV7, and
post-PCV13 periods included 70 (24.6%), 142 (49.8%),
and 73 (25.6%) isolates, respectively.
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Among the 285 invasive isolates, 280 (98.2%) strains
were typeable pneumococci. Of these typeable isolates, a
total of 30 serotypes were identified. The most common
serotype was 19A (n = 64, 22.9%), followed by 23F (n =
29, 10.4%), 19F (n = 25, 8.9%), 14 (n = 23, 8.2%), and 6B
(n = 23, 8.2%). PCV7 and PCV13 serotypes accounted
for 42.1% (n = 118) and 73.2% (n = 205) of all serotypes,
respectively. Throughout the 18-year period, there were
significant decreases in the proportions of PCV7 types
between the pre-PCV7 (n = 45, 67.1%) and post-PCV7
(n = 64, 46.7%) periods, and between post-PCV7 and
post-PCV13 periods (n = 7, 9.6%) (P = 0.019 and P <
0.001, respectively). The aPCV13 types increased
gradually from 21.4% (n = 15) in the pre-PCV7 to 32.8%
(n = 45) in the post-PCV7 period and then to 37.0% (n =
27) in the post-PCV13 period (P = 0.087 and P = 0.547,
respectively). NVTs increased significantly, but only be-
tween the post-PCV7 (n = 28, 20.4%) and post-PCV13
(n = 39, 53.4%) periods (P < 0.001).
Genotype diversity of invasive pneumococci recovered
from 1995 to 2013
A total of 81 STs with 10 CCs and 35 singletons were
assigned (Fig. 1). CC81, CC90, CC166, CC320, CC554,
and CC880 were associated with the well-known inter-
national Pneumococcal Molecular Epidemiology Net-
work (PMEN) clones Spain23F-1, Spain6B-2, Spain9V-3,
Taiwan19F-14, Spain14–5, and Taiwan23F-15, respectively.
Prevalent STs were ST320 (n = 66, 23.2%; 19A [n = 58],
19F [n = 7], 3 [n = 1]), ST81 (n = 18, 6.3%; 6A [n = 8], 23F
[n = 9], and 14 [n = 1]), ST166 (n = 15, 5.3%; 9 V [n = 9],
11A [n = 5], and 15C [n = 1]), and ST880 (n = 15, 5.3%;
all 23F). Among the 10 CCs identified in this study,
CC320 (n = 90 [31.6%], 11 STs) was the most common,
followed by CC81 (n = 42 [14.7%], 10 STs) and CC166
(n = 19 [6.7%], 3 STs).
Serotype changes in the main clonal complexes
CC320
CC320 remained the most dominant CC throughout all
three study periods. CC320 slightly increased from
24.3% (n = 17) in the pre-PCV7 to 33.8% (n = 48) in the
post-PCV7 period (P = 0.158) and then remained at
34.2% (n = 25) in the post-PCV13 period. The propor-
tion of 19A in CC320 increased from 52.9% (n = 9) to
64.6% (n = 31) and then to 92.0% (n = 23) in the
pre-PCV7, post-PCV7, and post-PCV13 periods, re-
spectively (Fig. 2a).
CC81
CC81 decreased significantly from 21.4% (n = 15) in the
pre-PCV7 period to 9.9% (n = 14) in the post-PCV7
period (P = 0.021) but increased to 19.2% (n = 14) in the
post-PCV13 period (P = 0.055). Serogroups 6, 13, 14, 15,
and 23 shared CC81, in which the PCV7 type decreased
significantly from 66.7% (n = 10; serotypes 14 [n = 2] and
23F [n = 8]) to 0% (P = 0.001), and the aPCV13 type and
NVT tended to increase from 6.7% (n = 1; serotype 6A)
to 36.4% (n = 4; all serotype 6A) (P = 0.169) and from
28.6% (n = 4; serotypes 13 [n = 1] and 15B/C [n = 3]) to
Fig. 1 eBURST diagram with the results of multilocus sequence typing of all study isolates (n = 285). Circle sizes correlate with the number of
isolates of each sequence type. International Pneumococcal Molecular Epidemiology Network clones associated with certain clonal complexes are
indicated in red. CC, clonal complex
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71.4% (n = 10; serotypes 6C [n = 1], 13 [n = 3], 15A [n =
4], and 15B/C [n = 2]) (P = 0.066), respectively, between
the pre-PCV7 and post-PCV13 periods (Fig. 2b).
CC166
The prevalence of CC166 almost unchanged between
the pre-PCV7 (4.3%, n = 3; all 9 V) and post-PCV7
periods (7.0%, n = 10; 9 V [n = 8] and 11A [n = 2]) (P =
0.552), and between the post-PCV7 and post-PCV13
periods (8.2%, n = 6; 9 V [n = 1], 11A [n = 3], and 15B/C
[n = 1]) (P = 0.756). The main serotype responsible for
CC166 changed from 9 V (100%) to 11A (50%) through-
out the study periods (Fig. 2c).
Genotypic changes in the main serotypes
Serogroup 6
In serogroup 6, CC81 and CC90 were the main geno-
types (n = 14, 33.3% in both; Table 1). Serotype 6A
mainly consisted of CC81 (25.0, 87.5, and 100% in the
pre-PCV7, post-PCV7, and post-PCV13 periods, re-
spectively), and those in the singleton STs (ST855,
ST3166, and ST3168) disappeared across the study
periods. In serotype 6B, the proportion of CC90 in-
creased from 55.6% (n = 13) to 100% (n = 1), but the
number of total isolates decreased significantly in the
post-PCV13 period. One isolate each of serotypes 6C
and 6D was first identified in the post-PCV7 period and
was assigned to ST5251 and ST11978, respectively,
which had not been reported before in serogroup 6, al-
though ST11978 was a ST of CC81. In the post-PCV13
period, one 6C isolate was identified in ST282, which
also included the 6A isolate.
Serotype 14
Serotype 14 exhibited a diverse genetic background in
the pre-PCV7 period, although CC554 was the main
genotype (n = 6, 54.5%; Table 1). As in serotype 6B,
another PCV7 type, the proportion of CC554 in serotype
14 increased to 100% in both the post-PCV7 (n = 11) and
post-PCV13 (n = 1) periods, but the total number of iso-
lates dramatically decreased in the post-PCV13 period.
Serogroup 15
In serogroup 15, there was only serotype 15B/C in the
pre-PCV7 period (n = 3), but serotype 15A appeared
thereafter. Most (n = 5, 83.3%) of serotype 15A had the
CC81 genotype, a main 15B/C genotype in the
pre-PCV7 period (Table 1). The 15B/C genotypes be-
came more diverse across the study periods, and ST3280
was the main genotype in the post-PCV7 (n = 4, 80.0%)
and post-PCV13 (n = 6, 66.7%) periods.
Serogroup 19
Serogroup 19 was so genetically homogeneous that
97.8% (n = 87) of the isolates belonged to only CC320. In
particular, ST320 in serotype 19A was significantly
prevalent (90.0%, 58/64). The proportion of ST320 in
serotype 19A did not change, remaining at 90.0% (n = 9,
pre-PCV7), 90.3% (n = 28, post-PCV7), and 91.3% (n =
21, post-PCV13) across the study periods. ST320 ap-
peared in serotype 19F (n = 7, 28.0%) in the post-PCV7
period but disappeared in the post-PCV13 period.
Serogroup 23
Similar to serotypes 6C/6D and 15A, serotypes 23A/23B
appeared in serogroup 23 beginning in the post-PCV7
period (Table 1). Many serotype 23F isolates belonging
to CC81 and CC880 were identified in the pre- and
post-PCV7 periods but mostly disappeared in the
post-PCV13 period. Serotypes 23A and 23B did not
share their genetic structures with any other serotypes in
this study, including serotype 23F.
Antimicrobial resistance changes in the main genotypes
Among the genotypes that included more than five
isolates, non-susceptibility to penicillin (42.3%) and
Fig. 2 Sequence type changes in the main genotypes CC320 (a), CC81
(b), and CC166 (c) across the study periods. In CC320, serotype 19A
increased from 52.9 to 64.6%, and then to 92.0% (a). In CC81, serotype
23F decreased significantly, whereas serotypes 6A, 13, and 15A increased
(b). The proportions of serotypes 9 V and 11A crossed over into CC166
during the study periods (c). PCV, pneumococcal conjugate vaccine;
MLST, multilocus sequence typing; CC, clonal complex; S, singleton
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Table 1 Sequence type changes in individual serotypes during the study periods
Serotype CC/ST (relation
to confounder)
CC percentage (n) of the serotype during n
Pre-PCV7
(1995–2003)
Post-PCV7
(2004–2010)
Post-PCV13
(2011–2013)
1 ST615 0 100 (1) 0 1
ST306 0 100 (1) 0 1
3 ST10002 0 100 (2) 0 2
CC320 0 100 (1) 0 1
ST320 0 100 (1) 0 1
4 ST899 0 100 (2) 0 2
5 CC439 100 (1) 0 0 1
ST3394 (SLV) 100 (1) 0 0 1
6A CC81 25.0 (1) 87.5 (7) 100 (4) 12
ST81 25.0 (1) 62.5 (5) 50.0 (2) 8
ST282 (SLV) 0 0 25.0 (1) 1
ST2842 (SLV) 0 25.0 (2) 25.0 (1) 3
ST855 25.0 (1) 12.5 (1) 0 2
ST3166 25.0 (1) 0 0 1
ST3168 25.0 (1) 0 0 1
6B CC90 55.6 (5) 61.5 (8) 100 (1) 14
ST90 11.1 (1) 0 0 1
ST95 (SLV) 22.2 (2) 0 0 2
ST1624 (SLV) 22.2 (2) 15.4 (2) 100 (1) 5
ST3175 (SLV) 0 7.7 (1) 0 1
ST3387 (SLV) 0 38.5 (5) 0 5
CC3173 11.1 (1) 38.5 (5) 0 6
ST3173 11.1 (1) 30.8 (4) 0 5
ST10274 (SLV) 0 7.7 (1) 0 1
ST3169 11.1 (1) 0 0 1
ST3171 22.2 (2) 0 0 2
6C CC81 0 0 100 (1) 1
ST282 (SLV) 0 0 100 (1) 1
ST5241 0 100 (1) 0 1
6D CC81 0 100 (1) 0 1
ST11978 (DLV) 0 100 (1) 0 1
7F ST191 0 100 (1) 0 1
9 V CC166 100 (3) 100 (8) 100 (1) 12
ST166 66.7 (2) 75.0 (6) 100 (1) 9
ST3383 (SLV) 33.3 (1) 0 0 1
ST10120 (SLV) 0 25.0 (2) 0 2
10A ST3385 0 100 (5) 83.3 (5) 10
ST11189 0 0 16.7 (1) 1
11A CC166 0 50.0 (2) 100 (4) 6
ST166 0 50.0 (2) 75.0 (3) 5
ST10120 (SLV) 0 0 25.0 (1) 1
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Table 1 Sequence type changes in individual serotypes during the study periods (Continued)
Serotype CC/ST (relation
to confounder)
CC percentage (n) of the serotype during n
Pre-PCV7
(1995–2003)
Post-PCV7
(2004–2010)
Post-PCV13
(2011–2013)
ST99 0 25.0 (1) 0 1
ST11188 0 25.0 (1) 0 1
12F ST220 0 100 (1) 0 1
ST6945 0 0 100 (1) 1
13 CC81 100 (1) 0 100 (3) 4
ST189 (SLV) 100 (1) 0 66.7 (2) 3
ST8420 (DLV) 0 0 33.3 (1) 1
14 CC81 18.2 (2) 0 0 2
ST81 9.1 (1) 0 0 1
ST3178 (SLV) 9.1 (1) 0 0 1
CC320 18.2 (2) 0 0 2
ST328 (DLV) 18.2 (2) 0 0 2
CC554 54.5 (6) 100 (11) 100 (1) 18
ST343 (SLV) 9.1 (1) 0 0 1
ST554 27.3 (3) 18.2 (2) 100 (1) 6
ST3177 (SLV) 9.1 (1) 27.3 (3) 0 4
ST3388 (DLV) 9.1 (1) 0 0 1
ST3600 (SLV) 0 9.1 (1) 0 1
ST3601 (SLV) 0 45.5 (5) 0 5
ST13 9.1 (1) 0 0 1
15A CC81 0 50 (1) 100 (4) 5
ST83 (SLV) 0 0 50 (2) 2
ST1591 (SLV) 0 50 (1) 50 (2) 3
ST3414 0 50 (1) 0 1
15B/C CC81 100 (3) 20.0 (1) 22.2 (2) 6
ST83 (SLV) 100 (3) 20.0 (1) 22.2 (2) 6
CC166 0 0 11.1 (1) 1
ST166 0 0 11.1 (1) 1
ST3280 0 80.0 (4) 66.7 (6) 10
16F ST8351 0 0 100 1
18C ST870 0 66.7 (2) 0 2
ST3180 100 (1) 0 0 1
ST3594 0 33.3 (1) 0 1
19A CC320 90.0 (9) 100 (31) 100 (23) 63
ST271 (SLV) 0 0 4.3 (1) 1
ST320 90.0 (9) 90.3 (28) 91.3 (21) 58
ST3159 (SLV) 0 0 4.3 (1) 1
ST4465 (SLV) 0 3.2 (1) 0 1
ST6398 (SLV) 0 3.2 (1) 0 1
ST6400 (SLV) 0 3.2 (1) 0 1
ST1374 10.0 (1) 0 0 1
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Table 1 Sequence type changes in individual serotypes during the study periods (Continued)
Serotype CC/ST (relation
to confounder)
CC percentage (n) of the serotype during n
Pre-PCV7
(1995–2003)
Post-PCV7
(2004–2010)
Post-PCV13
(2011–2013)
19F CC320 85.7 (6) 100 (16) 100 (2) 24
ST236 (DLV) 42.9 (3) 6.3 (1) 0 4
ST271 (SLV) 42.9 (3) 0 0 3
ST320 0 43.8 (7) 0 7
ST1464 (SLV) 0 43.8 (7) 50.0 (1) 8
ST2697 (SLV) 0 0 50.0 (1) 1
ST3390 (SLV) 0 6.3 (1) 0 1
ST2399 14.3 (1) 0 0 1
23A ST338 0 100 (4) 50.0 (2) 6
ST10272 0 0 50.0 (2) 2
23B CC439 0 0 50.0 (1) 1
ST439 0 0 50.0 (1) 1
ST2372 0 0 50.0 (1) 1
23F CC81 50.0 (8) 36.4 (4) 0 12
ST81 37.5 (6) 27.3 (3) 0 9
ST83 (SLV) 0 9.1 (1) 0 1
ST3392 (SLV) 6.3 (1) 0 0 1
ST3415 (SLV) 6.3 (1) 0 0 1
CC880 50.0 (8) 63.6 (7) 100 (2) 17
ST880 50.0 (8) 54.5 (6) 50.0 (1) 15
ST3176 (SLV) 0 9.1 (1) 50.0 (1) 2
24F CC90 50.0 (1) 0 0 1
ST3387 (SLV) 50.0 (1) 0 0 1
ST3386 0 0 100 (1) 1
ST3393 50.0 (1) 0 0 1
33F ST11188 0 100 (1) 100 (1) 2
34 CC9395 0 100 (3) 0 3
ST9395 0 66.7 (2) 0 2
ST11187 (SLV) 0 33.3 (1) 0 1
ST3116 100 (1) 0 0 1
35B CC558 100 (1) 100 (1) 0 2
ST558 100 (1) 100 (1) 0 2
37 ST447 0 0 100 (1) 1
NT CC90 0 20.0 (1) 0 1
ST3387 (SLV) 0 20.0 (1) 0 1
CC558 0 20.0 (1) 0 1
ST558 0 20.0 (1) 0 1
ST310 0 20.0 (1) 0 1
ST447 0 20.0 (1) 0 1
ST3386 0 20.0 (1) 0 1
CC clonal complex, ST sequence type, S singleton, PCV pneumococcal conjugate vaccine, n number, SLV single-locus variant, DLV double-locus variant,
NT non-typeable
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cefotaxime (62.0%) was the highest in CC320 (sero-
types 19A/19F [n = 70, 98.6%] and 14 [n = 1, 1.4%];
Table 2). All the isolates in CC320 that were
non-susceptible to penicillin or cefotaxime belonged
to serogroup 19. CC166 (serotypes 9 V [n = 10,
58.8%], 11A [n = 6, 35.3%], and 15C [n = 1, 5.9%])
showed non-susceptibility to penicillin (11.8%) and/or
cefotaxime (17.6%). All the isolates non-susceptible to
penicillin or cefotaxime in CC166 belonged to sero-
type 11A.
In contrast, non-susceptibility to chloramphenicol was
the highest in CC81 (94.4%; serotypes 6A/6C/6D [n = 13,
36.1%], 13 [n = 4, 11.1%], 14 [n = 1, 2.8%], 15A/15C [n =
8, 22.2%], and 23F [n = 10, 27.8%]) and the lowest in
CC880 (10.0%; all 23F [n = 10, 100%]). Serotype 23F iso-
lates in CC81 were all resistant to chloramphenicol, but
all except one isolate in CC880 were susceptible to the
antibiotic. Most isolates were highly non-susceptible to
tetracycline, clindamycin, and erythromycin, whereas
most study isolates except for one in CC320 (an isolate
in serotype 19A/ST320) were exclusively susceptible to
levofloxacin. CC166 and ST3280 (all serotype 15B/C)
were non-susceptible to trimethoprim-sulfamethoxazole.
Overall, CC320 showed the most multi-drug resistance,
whereas ST3385 (all serotype 10A) showed the most
susceptible patterns.
In CC320, all isolates were susceptible to penicillin
and cefotaxime in the pre-PCV7 period; however,
non-susceptibility increased to 76.0 and 68.0%, respect-
ively, in the post-PCV13 period. After applying the alter-
native breakpoints, all isolates were non-susceptible to
oral penicillin (0.06 μg/mL) throughout the three study
periods, and a similar trend was observed in cefotaxime
susceptibility with meningitis breakpoint (0.5 μg/mL).
Among the isolates with MIC data in CC320, the pro-
portions of serotype 19A were 0, 67.4% (n = 29), and
92.0% (n = 23) in the pre-PCV7, post-PCV7, and
post-PCV13 periods, respectively. However, serotypes
19A (67.4%) and 19F (32.6%) in CC320 did not exhibit
significant differences in non-susceptibility to penicillin
(27.6 and 21.4%, respectively; P = 1.000) or cefotaxime
(58.6 and 71.4%, respectively; P = 0.512) in post-PCV7
period. Serotype 19A/CC320 exhibited a significant
increase in non-susceptibility to penicillin (27.6 and
73.9%, respectively; P = 0.001) in the post-PCV7 and
post-PCV13 periods, although the increase in
non-susceptibility to cefotaxime was not significant (58.6
and 69.6%, respectively; P = 0.416).
Discussion
In this study, we investigated the genetic structures of
285 strains of S. pneumoniae isolated from Korean chil-
dren with IPD between 1995 and 2013. CC320, the most
common and antibiotic-resistant genotype, increased in
prevalence since the pre-PCV7 era, but the increase
nearly plateaued in the post-PCV13 era. However,
non-susceptibility to penicillin and cefotaxime increased
across the study periods among the strains within
CC320. After implementing PCV7 and PCV10/13, the
genotypes of PCV7 type invasive pneumococci isolated
from children during the pre-PCV7 period mostly disap-
peared (CC90, CC554, and CC880) and were
re-occupied by PCV13 types (CC320) or NVTs (CC81
and CC166) in the post-PCV13 period.
The genetic structures of clinical pneumococcal iso-
lates in Korea were previously investigated in children
under 5 years of age between 1995 and 2005 [11]. The
study included 77 invasive and 201 non-invasive
pneumococcal isolates, and the most prevalent clone
was ST320 (14.4%), which consisted of serotypes 19A
(87.5%) and 19F (12.5%). Other common clones were all
associated with PCV7 serotypes: ST81 (9.7%, 23F
[81.5%]), ST880 (9.4%, 23F [100%]), ST271 (5.0%, 19F
[100%]), ST166 (4.3%, 9 V [75.0%]), ST236 (4.3%, 19F
[100%]), and ST1464 (4.0%, 19F [100%]). Also among
the invasive isolates examined in the current study,
CC320 (including ST320, ST271, and ST236), CC81, and
CC166 were the most common genotypes in the
pre-PCV7 period (1995–2003), and they were largely oc-
cupied with the PCV7 types 14/19F (n = 8, 47.1%), 23F
(n = 8, 53.3%), and 9 V (n = 3, 100%), respectively.
The prevalence of the main CCs (CC320 and CC81)
did not change significantly in the post-PCV13 period
(34.2 and 17.8%, respectively) compared to the
pre-PCV7 period (24.3 and 21.4%, respectively). How-
ever, the main serotypes in the pre-PCV7 period within
CC320 and CC81 (19F and 23F, respectively) were
replaced by serotype 19A and serogroups 6 and 15, re-
spectively. In CC320, serotype 19A (n = 9, 52.9%;
aPCV13 type) was the main serotype in the pre-PCV7
Table 2 Antimicrobial non-susceptibility in the main genotypes
MLST n Non-susceptibility (%) to Antimicrobials
PCN CTX CLP TCL CLM ETM LFC TSZ
CC81 37 10.8 0 94.4 97.2 63.9 97.3 0 80.6
CC90 12 0 0 75.0 91.7 100 100 0 100
CC166 17 11.8 17.6 35.3 100 100 100 0 100
CC320 71 42.3 62.0 12.7 100 97.2 100 1.4 87.1
CC554 13 0 0 76.9 84.6 92.3 92.3 0 23.1
CC880 10 0 10 10.0 100 100 100 0 70.0
ST338 6 0 0 0 100 100 100 0 0
ST3280 9 0 0 0 100 0 100 0 100
ST3385 8 0 12.5 12.5 12.5 0 12.5 0 0
MLST multilocus sequence typing, CC clonal complex, ST sequence type, n
number, PCN penicillin, CTX cefotaxime, CLP chloramphenicol, TCL tetracycline,
CLM clindamycin, ETM erythromycin, LFC levofloxacin,
TSZ trimethoprim-sulfamethoxazole
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period; its proportion increased to 66.0% in the
post-PCV7 and to 92.0% in the post-PCV13 period. CC90,
CC554, and CC880 also decreased due to the decreases in
serotypes 6B, 14, and 23F, respectively, which all belonged
to the PCV7 serotype. CC166, the main CC of serotype
9 V in the pre-PCV7 period, increased because it was
re-occupied by serotypes 11A and 15C. In the other stud-
ies [17, 18], PCV13 decreased the frequency of PCV13
serotype-associated clones, and clonal shift was particu-
larly detected in the serotype 19A population. During the
years 2007–2012 in Canada, which implemented PCV13
in November 2010, CC320 and CC199 decreased to
almost 0% of the total isolates by 2012, whereas CC695
and CC191 became the predominant genotypes among
IPD in the same year. Several newly appeared STs found
in serotypes 19A and 15B/C indicating the possibility of
recent serotype switching events [18].
Serotype 19A has replaced many serotypes after the
introduction of PCV7 and is shown to be resistant to
penicillin; this change is believed to be associated mostly
with the clonal expansion of ST320 and ST199 [19, 20].
ST320 emerged as a predominant 19A clone after the
introduction of PCV7 but was nearly eliminated after
the change to PCV13 in the US. Therefore, most 19A
isolates were assigned to ST199 and ST695 in the early
PCV13 era [17, 21]. In clinical isolates collected from
children in Canada with IPD during 2007–2012, a
decline in 19A was observed in 2012. Additionally, a
clonal shift was detected in the 19A population as
CC320 and CC199 declined, whereas CC695 rose to a
majority in 2012, one year after the implementation of
PCV13 [18]. However, in Korea, 19A/ST320 was already
increased before PCV7 use [22] and has remained a
prevalent (n = 21, 28.8%) clone in the post-PCV13 era,
which may be explained by the study period shortly after
the implementation of PCV13 in this study. However,
serotype 19A in IPD decreased from 2011 to 2013 [10],
so that 19A/ST320 was expected to decrease rapidly
thereafter, especially after the use of PCV13 in the NIP.
The pattern of genotypic changes in serogroup 6 was
similar to that in serotype 14, as the numbers of isolates
and STs both decreased. CC90, the main genotype of
serotype 6B, mostly disappeared, whereas CC81, which
was previously associated with serotype 6A, was in-
creased in the post-PCV13 period. Although PCV7 (con-
taining 6B) and PCV13 (containing 6A/6B) were
considered to be cross-protective to serotypes 6A and
6C, respectively [23, 24], the effect was not prominent in
this study. Serotypes 6C in ST282 (post-PCV13 period)
and 6D in ST11978 (post-PCV7 period) may have devel-
oped on the genetic basis of serotype 6A in CC81, as
previously suggested [15].
In contrast to serogroups 6 and 14, serogroup 15 was
increased in the numbers of isolates, STs, and serotypes
across the study periods. Serotype 15B/C was expanded
to three STs (ST83, ST166, and ST3171). Serotype 15A
appeared in the post-PCV7 period and then expanded in
the post-PCV13 period. Serotypes 15A and 15B/C occu-
pied half of CC81, the genotype of the highly successful
MDR PMEN-1 clone. Serotype 15B/C showed increased
antimicrobial resistance and genetic complexity world-
wide and emerged in the post-PCV13 era [17, 18, 25].
Serotype 23F decreased stepwise after the use of PCV7
and PCV13, and serotypes 23A and 23B appeared in un-
related STs (ST338 and ST439/ST2372, respectively)
with other serotypes, including 23F. However, ST338
and ST439 both consisted of serotype 23F in the 1900s
and became the main genotype of serotypes 23A and
23B, respectively, according to the MLST database. Since
2008, ST2372 has only been reported in serotype 23B in
Europe. Therefore, serotypes 23A/23B may be imported
instead of capsular switching with isolates of other
serotypes in Korea. Similar to serogroup 15, serotype
23A has been noted recently in invasive diseases [26].
As mentioned before, in the US, PCV13 effectively de-
creased antimicrobial resistance, primarily due to the
elimination of the resistant serotype 19A/ST320. The
strain that contributes significantly to β-lactam resist-
ance since 2011–2013 is now 35B/ST558. Thus, clonal
expansion of the newly introduced resistant clone is
considered to be the main mechanism for the increase
in antibiotic resistance after the introduction of PCV13
in the US [4, 17]. However, in our study, there was a sig-
nificant increase in the non-susceptibility rate to penicil-
lin within a single clone, 19A/ST320 in post-PCV13
period compared to pre-PCV13 period, suggesting other
factors such as high exposure to antimicrobials contrib-
ute to the increase in MICs against penicillin within a
single drug-resistant clone.
Conclusions
This study was limited by including uneven data from
three different surveillance systems in the study period.
However, this was the largest and longest study on the
molecular epidemiology of IPD in Korean children. We
showed a comprehensive view of the genetic structures
of IPD isolates among children spanning the optional
use of PCV7 and PCV10/13 in Korea. Ongoing surveil-
lance and research on changes in the molecular epidemi-
ology of IPD after the introduction of PCV10/13 into
the NIP in 2014 is expected to elucidate the mechanisms
of serotype and antimicrobial changes in more detail
and to reveal emerging serotypes in IPD in children.
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